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Herpes Zoster Encephalitis: Successful Therapy with Vidarabinet 
Steven J. Wees, MD* and Tom Madhavan, MD'' 
A 77-year-old woman was seen who had encephalitis 
complicating trigeminal herpes zoster. Diagnosis was 
made by clinical and cerebrospinal fluid findings and 
electroencephalogram. As a result of parenteral vidarabine 
therapy, the patient recovered. 
H e r p e s zos te r is a c o m m o n i n f e c t i o n in i m m u n o -
compromised and debi l i tated elder ly patients and is life 
threatening in its visceral disseminated fo rm. Fortunately, a 
recent co l laborat ive ant iv iral study (1) by the Nat ional 
Institute of Al lergy and Infectious Diseases has shown that 
accelerated clearance of virus f rom the vesicles, cessation 
of new vesicle format ion, and a shorter t ime to total 
pustulation results w h e n herpes zoster is treated w i t h intra-
venous v idarabine (adenine arabinoside, ara-A). However , 
wh i l e this drug shows promise for therapy in i m m u n o c o m -
promised patients, its eff icacy has not been established in 
patients w i t h the visceral compl ica t ions of encephal i t is and 
pneumoni t is . Taber, et al reported no apparent benefi t o f 
v idarabine therapy in f ive patients w f th c l in ica l encepha-
litis secondary to herpes zoster (2). Contrary to this report, 
we have recently had good c l in ica l results using intra-
venous v idarabine to treat a patient w i t h herpes zoster 
encephal i t is comp l i ca t i ng t r igeminal herpes zoster. 
Case Report 
A 77-year-old black woman was admitted to Henry Ford Hospital 
after experiencing four days of pain and burning in the right 
periorbital region. She had diabetes mellitus with chronic renal 
failure, quiescent rheumatoid arthritis, congestive heart failure 
secondary to arteriosclerotic heart disease, mitral regurgitation, 
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and congenital ovalocytosis. Her medications on admission were 
insulin, furosemide, digoxin, and folic acid. She had no recent or 
past history of alcohol abuse. One day before admission, she 
noted blisters near her right eye and began to complain of 
excruciating pain there. She was nauseated and vomited several 
times the day before she was admitted. 
On admission, the patient was somnolent but arousable. She had 
no muscle weakness, tonic-clonic movements, or incontinence. 
Her temperature was 36°C, the blood pressure 140/70 mm Hg, 
and the respiratory rate was 20/mt. Hemorrhagic vesicles were 
noted primarily in the right first trigeminal dermatome and, to a 
lesser extent, on the right second trigeminal dermatome, and on 
the hard and soft palate bilaterally. The right upper and lower lids 
were moderately swollen, and numerous vesicles were present. A 
mucoid discharge was seen between the lids. The conjunctiva and 
cornea appeared free of inflammation, and the pupils were round, 
reactive to light, and pinpoint. The fundi could not be visualized. 
The patient had several soft anterior cervical nodes and slight 
nuchal rigidity Chest auscultation revealed bilateral inspiratory 
rales. The apical heart rate was 120/mt and intermittently irregu-
lar. There was generalized cardiomegaly; an S3 gallop and lll/VI 
systolic murmur were heard at the apex with radiation to the left 
axilla. The liver edge was palpable 6 cm below the right costal 
margin. The patient's hands showed chronic deformities of rheu-
matoid arthritis without acute synovitis. 
The patient followed simple commands well, and was oriented to 
time, place and person, but could not provide other useful 
information. Her cranial nerves were normal, and her motor 
function was intact. Deep tendon reflexes could not be elicited, 
except for 1 -(- biceps jerks bilaterally. Babinski sign was negative. 
No grasp or snout reflexes were noted. 
At admission, the results of her laboratory tests were hemoglobin 
7.6 gm%, WBC count 4,600 with 78% poly, 1% bands, 18% 
lymphocytes and 3% monocytes, BUN 68 mg%, creatinine 4.7 
mg%, calcium 8.3 mg, phosphate 6.8 mg%. The rest o f the tests 
were within normal limits. 
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We initially believed that the patient had herpes zoster involving 
the ophthalmic and maxillary divisions of the right trigeminal 
nerve with no eye involvement. Herpetic infection was confirmed 
by positive Tzanck smear. An electroencephalogram performed 
on the second hospital day revealed a severe diftuse disturbance 
of cerebral activity over both the hemispheres with prominent 
cortical and subcortical irritability. Cerebrospinal fluid was clear 
and colorless on four tests. There were 3-37 cells with 99% 
lymphocytes on differential count by cytocentrifuge. CSF protein 
ranged from 48-104 mg%, and glucose ranged from 49-125 (with 
RBS of 147 and 315, respectively). Gram stain and cultures for 
bacteria, tuberculosis, and fungi were negative. On the basis of 
the clinical presentation, EEG results, and CSF findings, a diag-
nosis of herpes zoster encephalitis was made. The patient was 
started on vidarabine intravenously on the second hospital day. 
Based on her renal function, she received 5 mg/kg/day intra-
venously for eight days (recommended dose is 15 mg/kg/day for 
those with normal renal function). She also received intravenous 
phenytoin prophylactically. A computerized axial tomograph 
scan of the brain on the fourth hospital day showed marked 
widening of the cerebral sulci. The ventricular system was not 
enlarged or displaced. An area of decreased density was seen in 
the right posterior frontal region without mass effect, compatible 
with a localized inflammation. 
After two days of intravenous vidarabine, the patient's mental 
status slowly began to improve and continued to do so during her 
stay. On the fourth day, she developed myoclonus of the left 
upper extremity and a positive Babinski reflex on the left, but 
these resolved within the next week. A repeat EEG five days after 
treatment with vidarabine showed improvement over the initial 
EEG, but a moderate diffuse encephalopathic pattern was still 
present, affecting cortical and subcortical structures over both 
hemispheres, with minimal emphasis over the right central parie-
tal region. When discharged, the patient was fully oriented and 
conversant, able to feed and bathe herself, and to walk with a 
cane. 
Her skin lesions of herpes zoster were treated with Burrow's 
solution, and no evidence of secondary infection was seen during 
hospitalization. Two days after vidarabine had been started, the 
lesions were becoming dry and crusting. Only crusted erosions 
and right periorbital edema were present on the fifth day of 
treatment. There was no evidence of hepatic, hematologic, or 
gastrointestinal side effects. 
Discussion 
Dissemination of herpes zoster virus may occur to skin and 
to viscera and is associated primarily with increased mor-
bidity rather than mortality. The central nervous system can 
be involved with localized or disseminated infection, in-
c lud ing two c l in ica l l y dist inct forms of encephal i t is, 
namely ophthalmic zoster wfth hemiplegia and diffuse 
encephalftis (4). As many as 40% of patients wfth uncom-
plicated zoster show a mild pleocytosis or slightly elevated 
protein in the cerebrospinal fluid or both, without any 
symptoms or signs of meningftis. Spinal nerve root and 
peripheral nerve involvement, and motor neuropathies 
wfth or without muscle paralysis are more commonly seen 
in zoster than is encephalftis (4). In varicella, on the other 
hand, encephalitis is 25 to 30 times more common than 
myelitis. Manifestations of herpes zoster encephalftis may 
appear within one week before a cutaneous eruption ap-
pears. Most cases occur within two weeks after a rash 
appears. Approximately one third of patients with enceph-
alitis manifest a distinct syndrome characterized by oph-
thalmic zoster and contralateral hemiplegia. 
The average age of reported patients was 43, ranging from 
four to 74 years, and men outnumbered women approxi-
mately two to one. Significant underlying disease was 
present in about one sixth of the patients. Headache was 
common in all patients, whereas altered states of con-
sciousness were more common in those with diffuse en-
cephalitis. Convulsions and ataxia are rarely present in 
patients with ophthalmic zoster and hemiplegia, but are 
not uncommon in the other group. The reverse is true of 
fever and hemiplegia. An unusually high frequency of 
cranial nerve involvement is associated with encephalitis 
(one out of three), even when the ophthalmic zoster and 
hemiplegia group is excluded. Cerebrospinal fluid findings 
include mononuclear pleocytosis ranging from 19 to 440 
cells/mm^ wfth moderate elevations of protein in one half 
and a normal sugar. Electroencephalograms are usually 
diffusely abnormal. Brain scan shows focal areas of in-
creased isotope uptake or an abnormal flow pattern. Ar-
teriograms may show segmental angiitis and numerous 
vascular occlusions (on the affected side). Granulomatous 
angiitis of intracranial vessels has also been noted at au-
topsy (4). 
The diffuse encephalitic syndrome carries a 33% mortality 
rate (4). However, only one fatal case of ophthalmic zoster 
with hemiplegia has been reported in a group of 14 pa-
tients, although seven patients had significant sequelae. 
Most of the deaths occurred in patients reported before 
1947, and this figure may be reduced by the supportive 
care available today. Significant sequelae consist of hemi-
plegia, dementia, ataxia, and aphasia. In most cases, hemi-
plegia is mi ld and resolves at the t ime of discharge. 
Therefore, in contrast to the high mortality rate associated 
with untreated herpes simplex encephalitis (3), most pa-
tients wfth herpes zoster encephalitis have a reasonably 
good prognosis, although significant sequelae do occur. 
Taber, et al, in a review of eight cases with clinical enceph-
alftis, found that central nervous system symptoms and 
signs began soon after dissemination and included obtun-
dation (5 patients), confusion (3), coma (1), hallucinations 
(1), and meningismus (2). All eight patients had a mono-
nuclear pleocytosis and elevated protein in the cerebrospi-
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nal fluid, and varicella-zoster (VZ) antibody was detected 
also. In one patient, the VZ virus was isolated from the 
cerebrospinal fluid. Only five patients received treatment. 
They also completed vidarabine therapy without toxicity, 
but wfthout apparent benefit. However, starting time and 
duration of treatment were not mentioned. Three of five 
patients who received treatment died, and two others had a 
slow, complicated recovery wfth residual neurological dys-
function. Thus, encephalitis as a complication of dissemi-
nated herpes zoster was associated with increased 
morbidity. The authors speculated that early treatment of 
localized herpes zoster with effective antiviral agents might 
well decrease the incidence of encephalitis, thereby reduc-
ing mortality. Early recognition and prompt institution of 
vidarabine therapy in encephalitis may have a beneficial 
effect in patients such as ours. 
The pathogenesis of encephalitis associated with zoster is 
not clear. Direct viral invasion of spinal cord and brain in 
two severely immunosuppressed patients wfth zoster was 
presumed after intranuclear inclusions and herpes-like par-
ticles were found in autopsy material (4). In addftion, the 
virus was isolated from the brain of one patient. The 
preponderance of zoster involving cranial nerves in cases 
of encephalftis also supports direct viral spread as a poten-
tial mechanism of pathogenesis. However, histopathologic 
studies suggested "postinfectious changes of hemorrhage 
and vasculitis." Perivascular demyelination has also been 
described as the characteristic lesion of diffuse encephalftis 
(4). 
Vidarabine was synthesized in 1960 for use as a potential 
cancer agent. Four years later, the drug was shown to have 
a broad spectrum of anti-viral activity in tissue culture, 
particularly for classic DNA viruses, including herpes sim-
plex, cytomegalovirus, and varicella-zoster virus. It is an 
analogue of the purine base adenine. Recent reports of its 
success in controlled studies in treating herpes simplex 
encephalftis make this an excellent chemotherapeutic 
agent recommended for systemic use in a serious virus 
infection (4). Although the precise site of drug action 
remains undetermined, the primary site appears to be DNA 
polymerase. 
Animal studies of both its clinical pharmacology and tox-
icity showed that vidarabine was less toxic and less immu-
nosuppressive than the other two purine analogues used to 
treat serious viral infections, namely cytosine arabinoside 
and iodoxuridine (5). Pharmacokinetic studies in humans 
revealed that, following a single intravenous infusion, good 
plasma levels of vidarabine were reached wfthin 30 min-
utes, then falling over an eight-hour period (half-life 1.5 hrs) 
(6). The kidney is the primary site of clearance. Because of 
its favorable properties, limited trials of vidarabine were 
undertaken in humans seriously infected with herpes sim-
plex virus, varicella-zoster, and cytomegalovirus. Since the 
results were generally favorable, large-scale control trials 
were made (1,3). Data in two studies strongly support the 
usefulness of vidarabine for systemic chemotherapy. 
Herpes simplex encephalitis is a potentially fatal disease 
when untreated. In a recent double-blind placebo control-
led study, Whitley, et al, reported 28 brain biopsy-proved 
cases. Among 18 who received vidarabine, the mortality 
was 28%. Seven ofthe 10 untreated cases died. The level of 
consciousness at the time of therapy was found to be a 
significant variable. The dosage recommended at present is 
15 mg/kg/day given intravenously in a concentration notto 
exceed 0.7 mg/ml, dueto low drug solubility. The low level 
of toxicity, coupled with the documented effectiveness of 
vidarabine when used early in the course of herpes simplex 
encephalitis, suggests that vidarabine should be started 
early in patients suspected of having the disease. Therapy 
can be terminated in five days in patients lacking virologic 
proofof diagnosis. For patients with proven disease, ten 
days of therapy is recommended. At these doses, toxic 
effects of vidarabine are minimal and consist of nausea and 
vomfting, weight loss, weakness and diarrhea. At higher 
doses, megaloblastosis of bone marrow, SCOT elevation, 
tremors, and thrombophlebftis at the intravenous site may 
occur. However, all ofthese adverse reactions are revers-
ible. 
A controlled trial of vidarabine in localized and dissemi-
nated herpes zoster was carried out by a collaborative 
antiviral study group sponsored by the National Instftute of 
Allergy and Infectious Diseases (1). All 87 patients received 
both drug and placebo during the trial: efther vidarabine 
(Group A) or placebo (Group B) during the first five days of 
the study, then the opposite regimen for a second five days. 
The drug was administered at a dosage of 10 mg/kg given 
intravenously over 12 hours. Progress ofthe infection was 
monitored daily, and the healing process was assessed by 
various parameters. The two study groups had similar 
characteristics. In spite of rapid natural healing, those 
receiving vidarabine over the first five days had accelerated 
clearance of virus from vesicles, cessation of new vesicle 
formation, and a shorter time to total pustulation. Factors 
modifying the response to therapy included age (virus 
clearance was significantly accelerated in patients younger 
than 30), underlying disease (patients with reticulo-endo-
thelial neoplasia cleared the virus from lesions at signffi-
cantly accelerated rates), and duration of zoster before 
therapy (most effective when administered during the first 
six days of disease) (1). However, results of therapy for six 
patients with visceral complications of encephalitis and 
pneumonftis were not encouraging. Two patients died of 
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unrelated causes after the study was completed. Two others 
died shortly after they were enrolled in the study. Both had 
received placebo, and their deaths were attributed to zos-
ter. Although results of this study were discouraging for 
disseminated visceral zoster, systemic vidarabine therapy 
appears promising in patients similar to our patient. 
The NIAID colloborative study showed that vidarabine is a 
promising drug for therapy in both localized and dissemi-
nated cutaneous herpes zoster in immunocompromised 
patients and the elderly. The outcome of our case supports 
its continued use in zoster encephalftis with an ongoing 
evaluation of its efficacy. 
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